TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03593811

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetogastrogram (MGG)
Description: MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
Study: NCT05043948

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: for evaluation of the genome-wide association study

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: for evaluation of the genome-wide association study

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: for evaluation of the genome-wide association study

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: for evaluation of the genome-wide association study
Study: NCT02469220

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low FODMAP
Description: Blinded food supplements containing only items with a low content of FODMAPs

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized FODMAP
Description: Blinded food supplements containing FODMAPs
Study: NCT04336241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Programmed death receptor (PD-1) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Programmed death receptor (PD-1) blocking antibody
Study: NCT02274220

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rapid advancement of feeds
Description: Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard advancement of feeds
Description: Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
Study: NCT04475107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine-Artesunate
Description: Pyramax

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01154452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT02709772

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Record Alert
Description: Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
Study: NCT01252641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-728-T
Description: Each infusion will be 5-30 billion modified CD4+ T-cells
Study: NCT02592395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation
Description: Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
Study: NCT04073901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrowns
Description: Adhesive monoblock restoration for pulpotomized primary molars

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrowns
Description: Adhesive monoblock restoration for pulpotomized primary molars
Study: NCT03424395

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized dietary and wellness program
Description: Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
Study: NCT03532022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort®
Description: Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
Study: NCT03210701

Intervention type: OTHER
Group type: OTHER
Intervention: A HIV POCT program adapted for & provided by community pharmacists
Description: Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
Study: NCT02545491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care for Child Development (CCD) program
Description: The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant and Young Child feeding training by World Vision
Description: Training on breastfeeding benefits, solid introduction and food safety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Infant and Young Child feeding training by World Vision
Description: Training on breastfeeding benefits, solid introduction and food safety
Study: NCT06372886

Intervention type: PROCEDURE
Intervention: portal/superior vein resection
Description: portal/superior vein resection

Intervention type: PROCEDURE
Intervention: portal/superior vein resection
Description: portal/superior vein resection
Study: NCT03859492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Digital Mammography
Description: High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
Study: NCT02581865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03922893

Intervention type: OTHER
Intervention: Family History Information
Description: The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.

Intervention type: OTHER
Intervention: Family History Information
Description: The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.

Intervention type: GENETIC
Intervention: ORAGENE
Description: Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.

Intervention type: GENETIC
Intervention: ORAGENE
Description: Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.

Intervention type: GENETIC
Intervention: Blood
Description: For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis

Intervention type: GENETIC
Intervention: Blood
Description: For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis

Intervention type: OTHER
Intervention: Skin Biopsy
Description: In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.

Intervention type: OTHER
Intervention: Skin Biopsy
Description: In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
Study: NCT01010672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
Study: NCT02908581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron 150 mg and Folic acid 0.5 mg
Description: Iron will be administered with folic acid orally
Study: NCT01226303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: see the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRA + IDA
Description: see the protocol
Study: NCT03914989

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: olfactory enrichment (essential oils)
Description: Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactory enrichment (essential oils)
Description: Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
Study: NCT04178577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Description: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
Study: NCT02529683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuvaring
Description: contraceptive vaginal ring with ethinyl estradiol and etonogestrel
Study: NCT03101046

Intervention type: DRUG
Group type: OTHER
Intervention: Cabazitaxel
Description: Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m² every 3 weeks up to 10 cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
Study: NCT02006186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bicycle Train
Description: The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
Study: NCT03333694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cutaneous Cream application
Description: Cutaneous Cream application twice daily with experimental (CLL442)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cutaneous Cream application
Description: Cutaneous Cream application twice daily with placebo
Study: NCT00766116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Mylotarg given 2 times over 2 weeks
Study: NCT02855242

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Counseling
Description: Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
Study: NCT00766116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Mylotarg given 2 times over 2 weeks
Study: NCT02855242

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controls Group
Description: Subjects not participating in any lifestyle counseling
Study: NCT04092998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermocautery circumcision
Description: Histopathological changes from thermocautery circumcision
Study: NCT00766116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Mylotarg given 2 times over 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Mylotarg given 2 times over 2 weeks
Study: NCT00718536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Addition of raltegravir 800 mg QD to HAART
Description: Addition of raltegravir 800 mg QD to HAART
Study: NCT03302143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided bone regeneration with Bovine Bone Mineral
Description: Guided bone regeneration with Bovine Bone Mineral

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration with freeze dried bone allograft
Description: Guided bone regeneration with freeze dried bone allograft
Study: NCT03654274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily
Study: NCT04219969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-MRI
Study: NCT02780596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item1
Description: Does CHILD NAME often wake one or more times during the night?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item1
Description: Does CHILD NAME often wake one or more times during the night?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item1
Description: Does CHILD NAME often wake one or more times during the night?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item2
Description: Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item2
Description: Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item2
Description: Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item3
Description: Do you think CHILD'S SLEEP is a problem?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item3
Description: Do you think CHILD'S SLEEP is a problem?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item3
Description: Do you think CHILD'S SLEEP is a problem?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item4
Description: Do you think CHILD NAME has a sleep problem?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item4
Description: Do you think CHILD NAME has a sleep problem?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item4
Description: Do you think CHILD NAME has a sleep problem?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item5
Description: Do you have any concerns about CHILD NAME'S sleep?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item5
Description: Do you have any concerns about CHILD NAME'S sleep?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item5
Description: Do you have any concerns about CHILD NAME'S sleep?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item5
Description: Do you have any concerns about CHILD NAME'S sleep?
Study: NCT03013829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KPD Educational Video
Description: LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
Study: NCT04172337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthier Choice Symbol
Description: The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthier Choice Symbol
Description: The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Equivalent label
Description: For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images.
Study: NCT04114513

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: NOVAPRODUKT, white powder 5 weeks intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: BENEO-Orafti, white powder 5 weeks intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pectin
Description: BANG \& BONSOMER GROUP OY, white powder 5 weeks intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-glucan
Description: Tate \& Lyle, white powder 5 weeks intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides
Description: FrieslandCampina, white powder 5 weeks intervention
Study: NCT01790789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily stress reduction program
Description: Subjects will participate in activities of a daily stress reduction program.

Intervention type: OTHER
Group type: OTHER
Intervention: Attention control
Description: Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
Study: NCT02017613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP6530
Description: Escalating doses starting at 25 mg BID